AVIR News and Press, Atea Pharmaceuticals Inc. From 12/05/23

2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares  ( HBANL ) +3% . Genmab  ( GMAB ) +3% . Losers: Fluence En...

First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study Plasma Pharmacokinetic (PK) Profiles of Bemnifosbuvir and Ruzasvir Were Not Affected by Food or Concomitant Dosing, Indicating Low Risk of Drug-Drug Interactions ...

2023-11-08 18:51:05 ET Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Conference Call November 08, 2023, 16:30 ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet ...

2023-11-08 16:22:07 ET More on Atea Pharmaceuticals Atea Pharmaceuticals: Hoping Its COVID Efforts Are Still Relevant Seeking Alpha’s Quant Rating on Atea Pharmaceuticals For further details see: Atea Pharmaceuticals GAAP EPS of -$0.40

P atient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24 Phase 2 bemnifosbuvir and ruzasvir combination trial for hepatitis C (HCV) advances, initial results from 60-patient lead-in cohort expected 1Q24...

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea manag...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Atea Pharmaceuticals Inc. (AVIR) is expected to report $-0.46 for Q3 2023

2023-11-07 17:35:56 ET More on Atea Pharmaceuticals Atea Pharmaceuticals: Hoping Its COVID Efforts Are Still Relevant Atea downgraded at JPMorgan on shrinking COVID opportunity Historical earnings data for Atea Pharmaceuticals Financial information for Atea P...

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced two upcoming poster presentations at The Liv...